Preclinical Testing of a New Dry Powder Aerosol Synthetic Lung Surfactant Formulation and Device Combination for the Treatment of Neonatal Respiratory Distress Syndrome
Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2025
DOI: 10.1089/jamp.2025.0001 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2025. Verfasst von Worth Longest und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Dry Powder Inhalers, Lung, Pulmonary Surfactants, Respiratory Distress Syndrome, Newborn. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study advanced the preclinical development of a new dry powder aerosol synthetic lung surfactant (SLS) product for neonatal respiratory distress syndrome (RDS) by integrating a multiple-actuation device and scalable spray-dried formulation, evaluating physicochemical and in vitro aerosol performance, and then comparing biological efficacy with the current clinical standard of high-volume liquid bolus instillation.
Methods
A new high-dose air-jet dry powder inhaler was developed that was characterized by a variable-volume aerosolization chamber (D3 device) with the goal of unifying aerosol quality and emitted dose (ED) over multiple actuations. The SLS excipient enhanced growth dry powder formulation was advanced through production on a scalable nozzle-based spray dryer system (Mini Spray Dryer; MSD2 formulation). Physicochemical characterization of the formulation was performed along with in vitro aerosol testing of the new D3-MSD2 device and formulation combination. The optimized D3-MSD2 aerosol therapy was then evaluated in a rabbit model of severe RDS.
Results
The new D3-MSD2 combination produced a small-particle aerosol with high fine particle fraction (FPF
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia, USA.
- Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA.
- Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.
ORCID-Profile: Worth Longest, Michael Hindle
Zitieren
APA
Longest, W., Hindle, M., Farkas, D., Momin, M. A. M., Dalton, C., Hall, F., Aladwani, G., KenKnight, H., & DiBlasi, R. M. (2025). Preclinical Testing of a New Dry Powder Aerosol Synthetic Lung Surfactant Formulation and Device Combination for the Treatment of Neonatal Respiratory Distress Syndrome. Journal of Aerosol Medicine and Pulmonary Drug Delivery. https://doi.org/10.1089/jamp.2025.0001
Vancouver
Longest W, Hindle M, Farkas D, Momin MAM, Dalton C, Hall F, et al. Preclinical Testing of a New Dry Powder Aerosol Synthetic Lung Surfactant Formulation and Device Combination for the Treatment of Neonatal Respiratory Distress Syndrome. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2025. doi:10.1089/jamp.2025.0001
BibTeX
@article{Longest2025,
author = {Longest, Worth and Hindle, Michael and Farkas, Dale and Momin, Mohammad A M and Dalton, Caleb and Hall, Felicia and Aladwani, Ghali and KenKnight, Hattie and DiBlasi, Robert M},
title = {Preclinical Testing of a New Dry Powder Aerosol Synthetic Lung Surfactant Formulation and Device Combination for the Treatment of Neonatal Respiratory Distress Syndrome},
journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
year = {2025},
doi = {10.1089/jamp.2025.0001}
}
EUVIMED